Global Adenosine Deaminase Deficiency Drugs

Adenosine Deaminase Deficiency Drugs Comprehensive Study by Type (Adagen, Revcovi), Application (Hospitals, Clinic, Ambulatory Surgical Centers), Sales Channel (Prescription Drugs, Over-the-Counter Drugs) Players and Region - Global Market Outlook to 2024

Adenosine Deaminase Deficiency Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Adenosine deaminase (ADA) deficiency, is an autosomal recessive genetic disorder that damages the immune system and causes severe combined immunodeficiency (SCID). It occurs in fewer than one in 100,1000 births globally, according to the World Health Organisation (WHO). Of late, Food & Drug Administrator (FDA) has granted approval to Revcovi injection in the United States) for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.This growth is primarily driven by Most States in the Developed Countries Screen Newborns for Combined Immune Deficiency (SCID).

Globally, a noticeable market trend is evident Research and Development in the Healthcare Industry. Major Players, such as Leadiant Biosciences (Italy), TEIJIN Limited (Japan), ENZON Pharmaceuticals, Inc. (United States) and Others etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In May 2019, Teijin pharma limited launched Revcovi 2.4 mg which is Japan’s first drug for Adnosine diaminase (ADA) deficiency, is an enzyme replacement therapy that is expected to improve ADA activity and the immune system of ADA-deficiency patients.

Market Drivers
  • Most States in the Developed Countries Screen Newborns for Combined Immune Deficiency (SCID)

Market Trend
  • Research and Development in the Healthcare Industry

Restraints
  • Stringent Government Regulations Regarding Drugs Approval
  • The Threat of Side Effects Associated With Adenosine Deaminase Deficiency Drugs

Opportunities
Technological Advancement in the Healthcare Industry and Increasing Investment in the Development of Healthcare Infrastructure in the Developing Economies
Challenges
Lack of Awareness in the Emerging Economies and Limited Number of Market Players

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Report Objectives / Segmentation Covered

By Type
  • Adagen
  • Revcovi
By Application
  • Hospitals
  • Clinic
  • Ambulatory Surgical Centers
By Sales Channel
  • Prescription Drugs
  • Over-the-Counter Drugs

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Most States in the Developed Countries Screen Newborns for Combined Immune Deficiency (SCID)
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness in the Emerging Economies
      • 3.3.2. Limited Number of Market Players
    • 3.4. Market Trends
      • 3.4.1. Research and Development in the Healthcare Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Adenosine Deaminase Deficiency Drugs, by Type, Application, Sales Channel and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Adenosine Deaminase Deficiency Drugs (Value)
      • 5.2.1. Global Adenosine Deaminase Deficiency Drugs by: Type (Value)
        • 5.2.1.1. Adagen
        • 5.2.1.2. Revcovi
      • 5.2.2. Global Adenosine Deaminase Deficiency Drugs by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinic
        • 5.2.2.3. Ambulatory Surgical Centers
      • 5.2.3. Global Adenosine Deaminase Deficiency Drugs by: Sales Channel (Value)
        • 5.2.3.1. Prescription Drugs
        • 5.2.3.2. Over-the-Counter Drugs
      • 5.2.4. Global Adenosine Deaminase Deficiency Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Adenosine Deaminase Deficiency Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Leadiant Biosciences (Italy)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. TEIJIN Limited (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. ENZON Pharmaceuticals, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Others
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
  • 7. Global Adenosine Deaminase Deficiency Drugs Sale, by Type, Application, Sales Channel and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Adenosine Deaminase Deficiency Drugs (Value)
      • 7.2.1. Global Adenosine Deaminase Deficiency Drugs by: Type (Value)
        • 7.2.1.1. Adagen
        • 7.2.1.2. Revcovi
      • 7.2.2. Global Adenosine Deaminase Deficiency Drugs by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinic
        • 7.2.2.3. Ambulatory Surgical Centers
      • 7.2.3. Global Adenosine Deaminase Deficiency Drugs by: Sales Channel (Value)
        • 7.2.3.1. Prescription Drugs
        • 7.2.3.2. Over-the-Counter Drugs
      • 7.2.4. Global Adenosine Deaminase Deficiency Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Adenosine Deaminase Deficiency Drugs: by Type(USD Million)
  • Table 2. Adenosine Deaminase Deficiency Drugs Adagen , by Region USD Million (2013-2018)
  • Table 3. Adenosine Deaminase Deficiency Drugs Revcovi , by Region USD Million (2013-2018)
  • Table 4. Adenosine Deaminase Deficiency Drugs: by Application(USD Million)
  • Table 5. Adenosine Deaminase Deficiency Drugs Hospitals , by Region USD Million (2013-2018)
  • Table 6. Adenosine Deaminase Deficiency Drugs Clinic , by Region USD Million (2013-2018)
  • Table 7. Adenosine Deaminase Deficiency Drugs Ambulatory Surgical Centers , by Region USD Million (2013-2018)
  • Table 8. Adenosine Deaminase Deficiency Drugs: by Sales Channel(USD Million)
  • Table 9. Adenosine Deaminase Deficiency Drugs Prescription Drugs , by Region USD Million (2013-2018)
  • Table 10. Adenosine Deaminase Deficiency Drugs Over-the-Counter Drugs , by Region USD Million (2013-2018)
  • Table 11. South America Adenosine Deaminase Deficiency Drugs, by Country USD Million (2013-2018)
  • Table 12. South America Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 13. South America Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 14. South America Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 15. Brazil Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 16. Brazil Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 17. Brazil Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 18. Argentina Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 19. Argentina Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 20. Argentina Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 21. Rest of South America Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 22. Rest of South America Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 23. Rest of South America Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 24. Asia Pacific Adenosine Deaminase Deficiency Drugs, by Country USD Million (2013-2018)
  • Table 25. Asia Pacific Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 26. Asia Pacific Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 27. Asia Pacific Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 28. China Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 29. China Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 30. China Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 31. Japan Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 32. Japan Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 33. Japan Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 34. India Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 35. India Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 36. India Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 37. South Korea Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 38. South Korea Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 39. South Korea Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 40. Taiwan Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 41. Taiwan Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 42. Taiwan Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 43. Australia Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 44. Australia Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 45. Australia Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 46. Rest of Asia-Pacific Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 47. Rest of Asia-Pacific Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 48. Rest of Asia-Pacific Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 49. Europe Adenosine Deaminase Deficiency Drugs, by Country USD Million (2013-2018)
  • Table 50. Europe Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 51. Europe Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 52. Europe Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 53. Germany Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 54. Germany Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 55. Germany Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 56. France Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 57. France Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 58. France Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 59. Italy Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 60. Italy Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 61. Italy Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 62. United Kingdom Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 63. United Kingdom Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 64. United Kingdom Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 65. Netherlands Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 66. Netherlands Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 67. Netherlands Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 68. Rest of Europe Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 69. Rest of Europe Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 70. Rest of Europe Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 71. MEA Adenosine Deaminase Deficiency Drugs, by Country USD Million (2013-2018)
  • Table 72. MEA Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 73. MEA Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 74. MEA Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 75. Middle East Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 76. Middle East Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 77. Middle East Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 78. Africa Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 79. Africa Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 80. Africa Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 81. North America Adenosine Deaminase Deficiency Drugs, by Country USD Million (2013-2018)
  • Table 82. North America Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 83. North America Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 84. North America Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 85. United States Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 86. United States Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 87. United States Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 88. Canada Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 89. Canada Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 90. Canada Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 91. Mexico Adenosine Deaminase Deficiency Drugs, by Type USD Million (2013-2018)
  • Table 92. Mexico Adenosine Deaminase Deficiency Drugs, by Application USD Million (2013-2018)
  • Table 93. Mexico Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2013-2018)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Adenosine Deaminase Deficiency Drugs: by Type(USD Million)
  • Table 99. Adenosine Deaminase Deficiency Drugs Adagen , by Region USD Million (2019-2024)
  • Table 100. Adenosine Deaminase Deficiency Drugs Revcovi , by Region USD Million (2019-2024)
  • Table 101. Adenosine Deaminase Deficiency Drugs: by Application(USD Million)
  • Table 102. Adenosine Deaminase Deficiency Drugs Hospitals , by Region USD Million (2019-2024)
  • Table 103. Adenosine Deaminase Deficiency Drugs Clinic , by Region USD Million (2019-2024)
  • Table 104. Adenosine Deaminase Deficiency Drugs Ambulatory Surgical Centers , by Region USD Million (2019-2024)
  • Table 105. Adenosine Deaminase Deficiency Drugs: by Sales Channel(USD Million)
  • Table 106. Adenosine Deaminase Deficiency Drugs Prescription Drugs , by Region USD Million (2019-2024)
  • Table 107. Adenosine Deaminase Deficiency Drugs Over-the-Counter Drugs , by Region USD Million (2019-2024)
  • Table 108. South America Adenosine Deaminase Deficiency Drugs, by Country USD Million (2019-2024)
  • Table 109. South America Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 110. South America Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 111. South America Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 112. Brazil Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 113. Brazil Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 114. Brazil Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 115. Argentina Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 116. Argentina Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 117. Argentina Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 118. Rest of South America Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 119. Rest of South America Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 120. Rest of South America Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 121. Asia Pacific Adenosine Deaminase Deficiency Drugs, by Country USD Million (2019-2024)
  • Table 122. Asia Pacific Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 123. Asia Pacific Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 124. Asia Pacific Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 125. China Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 126. China Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 127. China Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 128. Japan Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 129. Japan Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 130. Japan Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 131. India Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 132. India Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 133. India Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 134. South Korea Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 135. South Korea Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 136. South Korea Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 137. Taiwan Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 138. Taiwan Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 139. Taiwan Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 140. Australia Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 141. Australia Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 142. Australia Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 143. Rest of Asia-Pacific Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 144. Rest of Asia-Pacific Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 145. Rest of Asia-Pacific Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 146. Europe Adenosine Deaminase Deficiency Drugs, by Country USD Million (2019-2024)
  • Table 147. Europe Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 148. Europe Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 149. Europe Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 150. Germany Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 151. Germany Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 152. Germany Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 153. France Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 154. France Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 155. France Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 156. Italy Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 157. Italy Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 158. Italy Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 159. United Kingdom Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 160. United Kingdom Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 161. United Kingdom Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 162. Netherlands Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 163. Netherlands Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 164. Netherlands Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 165. Rest of Europe Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 166. Rest of Europe Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 167. Rest of Europe Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 168. MEA Adenosine Deaminase Deficiency Drugs, by Country USD Million (2019-2024)
  • Table 169. MEA Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 170. MEA Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 171. MEA Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 172. Middle East Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 173. Middle East Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 174. Middle East Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 175. Africa Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 176. Africa Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 177. Africa Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 178. North America Adenosine Deaminase Deficiency Drugs, by Country USD Million (2019-2024)
  • Table 179. North America Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 180. North America Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 181. North America Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 182. United States Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 183. United States Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 184. United States Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 185. Canada Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 186. Canada Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 187. Canada Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 188. Mexico Adenosine Deaminase Deficiency Drugs, by Type USD Million (2019-2024)
  • Table 189. Mexico Adenosine Deaminase Deficiency Drugs, by Application USD Million (2019-2024)
  • Table 190. Mexico Adenosine Deaminase Deficiency Drugs, by Sales Channel USD Million (2019-2024)
  • Table 191. Research Programs/Design for This Report
  • Table 192. Key Data Information from Secondary Sources
  • Table 193. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Adenosine Deaminase Deficiency Drugs: by Type USD Million (2013-2018)
  • Figure 5. Global Adenosine Deaminase Deficiency Drugs: by Application USD Million (2013-2018)
  • Figure 6. Global Adenosine Deaminase Deficiency Drugs: by Sales Channel USD Million (2013-2018)
  • Figure 7. South America Adenosine Deaminase Deficiency Drugs Share (%), by Country
  • Figure 8. Asia Pacific Adenosine Deaminase Deficiency Drugs Share (%), by Country
  • Figure 9. Europe Adenosine Deaminase Deficiency Drugs Share (%), by Country
  • Figure 10. MEA Adenosine Deaminase Deficiency Drugs Share (%), by Country
  • Figure 11. North America Adenosine Deaminase Deficiency Drugs Share (%), by Country
  • Figure 12. Global Adenosine Deaminase Deficiency Drugs share by Players 2018 (%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. Leadiant Biosciences (Italy) Revenue, Net Income and Gross profit
  • Figure 15. Leadiant Biosciences (Italy) Revenue: by Geography 2018
  • Figure 16. TEIJIN Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 17. TEIJIN Limited (Japan) Revenue: by Geography 2018
  • Figure 18. ENZON Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. ENZON Pharmaceuticals, Inc. (United States) Revenue: by Geography 2018
  • Figure 20. Others Revenue, Net Income and Gross profit
  • Figure 21. Others Revenue: by Geography 2018
  • Figure 22. Global Adenosine Deaminase Deficiency Drugs: by Type USD Million (2019-2024)
  • Figure 23. Global Adenosine Deaminase Deficiency Drugs: by Application USD Million (2019-2024)
  • Figure 24. Global Adenosine Deaminase Deficiency Drugs: by Sales Channel USD Million (2019-2024)
  • Figure 25. South America Adenosine Deaminase Deficiency Drugs Share (%), by Country
  • Figure 26. Asia Pacific Adenosine Deaminase Deficiency Drugs Share (%), by Country
  • Figure 27. Europe Adenosine Deaminase Deficiency Drugs Share (%), by Country
  • Figure 28. MEA Adenosine Deaminase Deficiency Drugs Share (%), by Country
  • Figure 29. North America Adenosine Deaminase Deficiency Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Leadiant Biosciences (Italy)
  • TEIJIN Limited (Japan)
  • ENZON Pharmaceuticals, Inc. (United States)
  • Others
Select User Access Type

Key Highlights of Report


Oct 2019 241 Pages 63 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Adenosine Deaminase Deficiency Drugs Quantitative research analysis
Global Adenosine Deaminase Deficiency Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Adenosine Deaminase Deficiency Drugs Report?

Have a Query? Click Here

Other Related Reports

Bio-protein Drug Comprehensive Study by Type (Monoclonal Antibodies, Recombinant Protein, Therapeutic Proteins, Vaccines), Application (Pharma and Biotech Companies, Clinical Research Organizations, ...
$ 3650
Sumatriptan Succinate Comprehensive Study by Application (Migraine, Cluster Headache), Mode Of Administration (Oral, Subcutaneous Injection), Form (Tablet, Injection, Spray), Distribution Channel (On...
$ 3450
Biopharmaceutical Logistics - Comprehensive Study by Type (Cold-chain Transport, Non-Cold-chain Transport.), Storage (Storage, Transportation, Monitoring Components), Transportation (Air Shipping, Ra...
$ 3650
Antimicrobial Gel Comprehensive Study by Type (Silver Antimicrobial Gel, Iodine Antimicrobial Gel, Others), Application (Home Use, Hospital Use), Distribution Channel (Hospital Pharmacies, Retail Pha...
$ 3350
Iloprost Drugs Comprehensive Study by Type (OTC, Prescribed), Application (Pulmonary Arterial Hypertension (PAH), High Blood Pressure), Route of Administration (Intravenous, Respiratory (Inhalation))...
$ 3450
Granisetron Comprehensive Study by Application (Chemotherapy, Radiotherapy, Nausea, Gastroparesis, Postoperative), Forms (Injection, Tablet, Syrup, Tablet, Oral Drops), Drug type (Generic drug, Paten...
$ 3350